Determination of cut-offs for circulating tumor cell measurement in metastatic cancer. Issue 9 (September 2011)

• Record Type: Journal Article
• Authors: Jacob, Jimmy; Krell, Jonathan; Castellano, Leandro; Jiao, Long R; Stebbing, Justin; Frampton, Adam E
• Is Part Of: Expert review of anticancer therapy. Volume 11:Issue 9(2011)
• Page Start: 1345
• Page End: 1350
• Publication Date: 2011-09
• Subjects: CirCe01 -- circulating tumor cells -- IC 2006-04 -- metastatic breast cancer -- overall survival -- progression-free survival -- serum markers -- SWOG-0500; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/era.11.133
• Languages: English
• ISSNs: 1473-7140

Abstract

Evaluation of: Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. DOI: 10.1093/annonc/mdr263 (2011) (Epub ahead of print). The metastatic transformation of epithelial tumors progresses through various steps leading to the generation of circulating tumor cells (CTCs). Measurement of CTCs in the peripheral blood is being increasingly recognized as a promising tool in breast oncology. Several studies have evaluated the prognostic significance of CTCs in newly diagnosed metastatic breast cancer (MBC) patients. The IC 2006-04 was a high-powered, prospective, multicenter, observational study conceived to assess CTC changes in women with MBC treated with first-line chemotherapy. Levels ≥5 CTCs/7.5 ml blood at baseline and before the second cycle of treatment were independent prognostic factors associated with shorter progression-free and overall survival. This study provides further level II evidence for the clinical and prognostic value of CTCs in MBC, confirming data from earlier small studies. It also provides proof that CTCs should be investigated in ongoing interventional trials to see if better patient outcomes can be attained by altering treatment based on CTC levels.